News

The Phase I trial is intended to investigate single escalating doses of 1, 5, or 10mg/kg of Valortim (or placebo) administered intravenously over a 120 minute infusion period.

Access Pharma will offer its CobaCyte and CobOral technology to the pharma firm for assessing gene knockdown after oral and intravenous administration. Any successful formulation developed will be

The two patents cover lipid nanoparticle (LNP) manufacturing process and the chemical modification of siRNA to mitigate immune stimulation. Tekmira Pharma said with the issuance of US patent

In particular, the patents cover the selection of NSCLC patients for treatment with antibodies directed against the epidermal growth-factor receptor (EGFR) pathway. The patents also cover the selection

Under this program, Center for Translational Research (CTR), a part of CHI’s Institute for Research and Innovation, will provide fresh human tumor samples for CDAS to perform biomarker

In line with its strategy, the acquisition expands Medivir’s commercial activities in the Nordic countries and creates the platform for the expected launch and commercialization of TMC435. BioPhausia

Conventional insecticides, such as DDT, kill mosquitoes as soon as they are exposed to the chemical, but their indiscriminate action speeds up the evolution of the insect towards

The study results suggested that MK has showed 27% reduction in the area of heart muscle damage as compared to untreated animals undergoing the same procedure. Dose-ranging studies

The objective of the trial is to measure the safety and tolerability of hGH-CTP and to assess dose ranging and dose response. The trial is enrolling up to